Group sales grew by 7%1 at constant exchange rates (CER; 3% in CHF), driven by strong demand for both medicines and diagnostics.Excluding COVID-19, Group sales increased by 9%.
The firm will share new overall survival data from the INAVO120 trial with regulators to support the breast cancer drug's approval.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback